IMPDH2 and cancer: IMPDH2 is overexpressed in hematological malignancies, including human leukemic cell lines and BCR-ABL-positive acute myelogenous leukemia [4], in chronic myelogenous leukemia [5] and other cancers, such as triple-negative breast cancer [6], prostate cancer [7,8], kidney cancer [9], nasopharyngeal carcinoma [10], in a subset of small-cell lung cancers [3,11], in non-small cell lung cancer [12] and in glioblastoma [13,14] and brain metastases [15].